Rejuvitas provides novel gene therapies employing metabolic reprogramming and regenerative medicine technologies developed in the lab of acclaimed geneticist, Stephen Tsang, M.D., PhD. The company is a MEC (Medical Excellence Capital) company creation founded along with Dr. Tsang, using IP licensed from Columbia University. In addition, Alexandria Technology Ventures has invested alongside. Rejuvitas is developing genetic and metabolic regenerative medicine therapies that address the underlying common cause of retinal degeneration and several significant neurodegenerative diseases. The lead program is targeting Retinitis Pigmentosa, a rare genetic disorder of the retina.
Location: United States, New York
Employees: 1-10
Founded date: 2021
Investors 1
| Date | Name | Website |
| - | Medical Ex... | medexcelca... |
Mentions in press and media 1
| Date | Title | Description |
| 09.09.2022 | Meet John Prufeta, General Partner of Medical Excellence Capital | MEC invests in cell therapy, gene therapy, regenerative medicine, synthetic biology, and AI Venture capital used to be a cottage industry, with very few investing in tomorrow's products and services. Oh, how times have changed! While there ... |